Insights

Strategic Collaboration Oncotelic’s partnership and joint venture-driven model presents opportunities for B2B collaborations, licensing agreements, and supply chain engagement, particularly with companies interested in late-stage clinical therapeutics and innovative drug delivery platforms.

Focus on Technologies The company’s development of ultra small molecular nanomedicine and AI-driven platforms like PDAOAI suggests potential for technology licensing, custom AI solutions, and integrated technology partnerships with organizations seeking advanced biomedical data analysis and targeted delivery solutions.

Pipeline Expansion Oncotelic's focus on TGFB2 therapeutics and its late-stage clinical programs creates sales opportunities for clinical research services, specialized diagnostic tools, biomarker development, and companion diagnostics tailored to oncology and immunotherapy markets.

Market Positioning The company's recent M&A activity and increased IP coverage indicate a strengthening competitive stance, opening avenues for investment, co-development deals, and strategic alliances with biopharma firms aiming to expand their oncology and CNS treatment portfolios.

Funding & Growth With revenue in the range of one to ten million dollars and an active focus on advancing late-stage assets, there are opportunities to provide clinical trial support, manufacturing partnerships, and commercialization services to support Oncotelic’s growth trajectory.

Oncotelic Tech Stack

Oncotelic uses 8 technology products and services including Amazon S3, WordPress, MySQL, and more. Explore Oncotelic's tech stack below.

  • Amazon S3
    Content Delivery Network
  • WordPress
    Content Management System
  • MySQL
    Database
  • oEmbed
    Dev Tools
  • WooCommerce
    E-commerce
  • Font Awesome
    Font Scripts
  • DataTables
    Javascript Libraries
  • Google Tag Manager
    Tag Management

Media & News

Oncotelic's Email Address Formats

Oncotelic uses at least 1 format(s):
Oncotelic Email FormatsExamplePercentage
First.Last@oncotelic.comJohn.Doe@oncotelic.com
38%
FLast@oncotelic.comJDoe@oncotelic.com
22%
Last@oncotelic.comDoe@oncotelic.com
3%
First.Last@oncotelic.comJohn.Doe@oncotelic.com
37%

Frequently Asked Questions

Where is Oncotelic's headquarters located?

Minus sign iconPlus sign icon
Oncotelic's main headquarters is located at 29397 Agoura Road 107 Calabasas, California 91301 United States. The company has employees across 2 continents, including North AmericaEurope.

What is Oncotelic's stock symbol?

Minus sign iconPlus sign icon
Oncotelic is a publicly traded company; the company's stock symbol is OTLC.

What is Oncotelic's official website and social media links?

Minus sign iconPlus sign icon
Oncotelic's official website is oncotelic.com and has social profiles on LinkedInCrunchbase.

What is Oncotelic's SIC code NAICS code?

Minus sign iconPlus sign icon
Oncotelic's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Oncotelic have currently?

Minus sign iconPlus sign icon
As of February 2026, Oncotelic has approximately 21 employees across 2 continents, including North AmericaEurope. Key team members include Bioinformatic Specialist: S. Q.Attorney At Law: T. L.. Explore Oncotelic's employee directory with LeadIQ.

What industry does Oncotelic belong to?

Minus sign iconPlus sign icon
Oncotelic operates in the Biotechnology Research industry.

What technology does Oncotelic use?

Minus sign iconPlus sign icon
Oncotelic's tech stack includes Amazon S3WordPressMySQLoEmbedWooCommerceFont AwesomeDataTablesGoogle Tag Manager.

What is Oncotelic's email format?

Minus sign iconPlus sign icon
Oncotelic's email format typically follows the pattern of First.Last@oncotelic.com. Find more Oncotelic email formats with LeadIQ.

Oncotelic

Biotechnology ResearchCalifornia, United States11-50 Employees

Oncotelic is a clinical stage biotechnology company advancing therapies for cancer and other serious diseases by addressing the real reasons most drugs fail in the clinic. We do not build fragile single asset stories. We operate a partnership and joint venture driven model designed to accelerate development, manage risk intelligently, and create clear paths to value. We are biology first, execution driven, and grounded in clinical reality.
Too many promising therapies fail not because the science is wrong, but because execution is incomplete. We see cancer treatments break down due to immune suppression, fibrosis, poor tissue penetration, resistance mechanisms, and delivery limitations. When these challenges are compounded by long development timelines, capital inefficiency, and unclear exit pathways, innovation stalls and opportunity is lost for patients and investors alike. 
The industry does not need more speculative targets. It needs clinically validated biology, smarter delivery, and disciplined execution.
What sets Oncotelic apart?
• We advance TGFB2 based therapeutics targeting a master regulator of tumor immune evasion, fibrosis, and treatment resistance, with programs progressed into late stage clinical development through strategic joint ventures
• We build through Sapu Therapeutics, our majority owned joint venture combining TGFB2 programs with next generation molecular nanomedicine and a defined Hong Kong IPO pathway
• We develop ultra small molecular nanomedicine technology designed for deep tissue penetration, improved pharmacology, and differentiated clinical performance
• We created PDAOAI, a patented AI driven evidence interrogation platform that enables hypothesis generation, biomarker discovery, and translational insight
• We operate a capital efficient partnership model that creates multiple shots on goal while preserving clinical rigor and investor clarity
Oncotelic’s mission is to transform how hard to treat diseases are addressed by aligning b

Section iconCompany Overview

Headquarters
29397 Agoura Road 107 Calabasas, California 91301 United States
SIC Code
8733 - Noncommercial Research Organizations
Stock Symbol
OTLC
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Employees
11-50

Section iconFunding & Financials

  • $1M$10M

    Oncotelic's revenue is estimated to be in the range of $1M$10M

Section iconFunding & Financials

  • $1M$10M

    Oncotelic's revenue is estimated to be in the range of $1M$10M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.